Description
Omacetaxine Mepesuccinate, marketed under the brand name SYNRIBO, It is an prescription medication that has been approved omacetaxine mepesuccinate (brand name Synribo) on October 26, 2012. The FDA granted accelerated approval for this drug to treat adult patients with chronic or accelerated phase chronic myeloid leukemia (CML).
What is SYNRIBO (omacetaxine mepesuccinate) ?
SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia
(CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate.
There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.
How to order approved “SYNRIBO (omacetaxine mepesuccinate) for Injection” Medicine?
SYNRIBO (Omacetaxine Mepesuccinate) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing SYNRIBO and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
We can ship to :
Verve Biosciences offers assistance in importing the anti-cancer medication SYNRIBO (omacetaxine mepesuccinate) for Injection. To inquire about the total cost of SYNRIBO (omacetaxine mepesuccinate) for Injection in various countries, including UAE, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, as well as Europe (such as UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithania, Greece, Spain, Maldova, Germany, Sweden, Italy, Bulgaria, Romania, Montenegro, Russia), and other countries like Zimbabwe, Australia, and New Zealand, Canada, Philippines, USA, South Africa, Thailand, China, Pakistan, Kazakhstan, Uzbekistan, Zambia, Kuwait, Sri Lanka, Singapore, Hong Kong, Afghanistan, Turkey, Malaysia, Qatar, Japan, Nepal, and many other countries. please reach out to us. We will provide you with the necessary information regarding the pricing and availability of SYNRIBO (omacetaxine mepesuccinate) for Injection in the desired locations.
How to Get Access
If the Brand Name medication “SYNRIBO (omacetaxine mepesuccinate) for Injection” is not approved or unavailable in your country, patients, physicians, and distributors/suppliers have the option to purchase and import it from Verve Biosciences. To begin the process, you can make an enquiry, and we will assist you in calculating the total cost to buy “SYNRIBO (omacetaxine mepesuccinate) for Injection” online and arrange delivery to your location. To proceed, we will require a prescription from your treating doctor, and in certain countries, an import license may also be necessary. Throughout the process, our Patient Support team will provide guidance and support.
Verve Biosciences Pvt. Ltd.
Contact Person : Mr Rakesh Khanna
Email: info@cancermedicinesnetwork.com
Mobile: 91 9910645395
WhatsApp: +919910645395
FAQ's
How much does SYNRIBO cost?
The SYNRIBO price in India usually can vary depending on the wholesaler/pharmacy you visit. SYNRIBO is available as a brand name drug only, a generic version is not yet available.
What is the best price for omacetaxine mepesuccinate?
Please contact at urgent@cancermedicinesnetwork.com : (+91) 9910645395 for omacetaxine mepesuccinate price India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Can I get SYNRIBO (omacetaxine mepesuccinate) for Injection even if I am not based in India?
The Verve Biosciences helps patients in accessing or importing SYNRIBO (omacetaxine mepesuccinate), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.
